Decrease in hepatitis B prevalence among blood donors in Central-West Brazil
Journal of Venomous Animals and Toxins including Tropical Diseases volume 19, Article number: 7 (2013)
The aim of the present study was to estimate hepatitis B virus seroprevalence among first-time blood donors in the city of Campo Grande, Mato Grosso do Sul State, in the central-western region of Brazil.
A retrospective analysis of first-time voluntary blood donor records, from January 2010 to December 2010, was conducted at the Hematology Center of Mato Grosso do Sul. The prevalence of the HBsAg and anti-HBc serological markers and their respective 95% confidence intervals were calculated. Chi-square analysis was performed between the seroprevalence previously found in 2001 and the one determined by the current study. Results were considered statistically significant if p < 0.05. Among 8,840 subjects, 269 (3.04%, 95% CI: 2.7-3.4) were positive for HBV markers. The prevalence rate of HBsAg was 0.19% (95% CI: 0.1-0.3) and anti-HBc alone was 2.85% (95% CI: 2.5-3.2).
There was no statistically significant difference regarding gender. However, an important association was observed between HBV infection and older age (p < 0.01). The seroprevalence of HBV infection in first-time blood donors diminished from 2001 to 2010 (p < 0.01). Such decrease suggests an improvement in the recruitment of safe donors, the positive impact of vaccination programs and the decreasing of HBV infection prevalence in the general population.
Parenteral exposure has been shown to be associated with hepatitis B virus (HBV) infection. Blood transfusions carry the risk of transfusion-transmitted infections such as hepatitis B and C. In order to measure their severity, the World Health Organization has recommended a pre-transfusion blood test. The residual risk of infection from HBV is higher than that of hepatitis C virus (HCV) in non-endemic countries .
In 1971, hepatitis B surface antigen (HBsAg) test was introduced for screening blood donors, and after 1986, antibody tests to hepatitis B core antigen (anti-HBc) were implemented to further reduce the risk of infectious agents in the blood supply .
The prevalence of infection in the general population varies in different regions of the world. Although Brazil is considered a low endemic country, there are areas that are highly endemic for HBV in the Amazon region . In Brazil, among blood donors, the prevalence ranges from 0.3% to 1.5% for HBsAg and from 3.7% to 11.1% for anti-HBc [4, 6, 7].
The aim of the present study was to estimate the seroprevalence of HBV infection among first-time blood donors in the city of Campo Grande, the capital city of the state of Mato Grosso do Sul, in the central-western region of Brazil.
A retrospective analysis of blood donor data from January 2010 to December 2010 was conducted in the Hematology Center of Mato Grosso do Sul (HEMOSUL). People who attended the center voluntarily for their first blood donation were selected by the standard criteria for healthy blood donors after answering a standardized questionnaire to evaluate epidemiological data. First-time blood donor was defined as a donor who donated for the first and only time. The protocol used in the present study was approved by the Ethics Committee of the Federal University of Mato Grosso do Sul.
Blood donor samples were screened for the presence of HBsAg and total anti-HBc by enzyme-linked immunosorbent assays (ELISA) (bioMérieux, Netherlands). Positive samples were retested using the same serological assay.
The prevalence of the HBsAg and anti-HBc serological markers and their respective 95% confidence intervals (95% CI) were determined. Chi-square analysis was performed between the seroprevalence published in 2001 and seroprevalence found in this study (2010) and was considered statistically significant if p < 0.05.
A total of 8,840 first-time blood donors aged between 18 to 65 years, who were considered healthy individuals and eligible for blood donation, participated in this study. The majority of individuals were males (60.6%, n = 5,358) between 18 and 39 years old (81.2%, n = 7,074), representing typical characteristics of blood donors in Brazil. Among the 8,840 subjects, 269 (3.04%, 95% CI: 2.7-3.4) were positive for HBV markers. The prevalence rate of HBsAg was 0.19% (95% CI: 0.1-0.3) and anti-HBc alone was 2.85% (95% CI: 2.5-3.2). There was no statistically significant difference with respect to gender. A significant association was observed between HBV infection and older age (p < 0.01) (Table 1).
As shown in Table 2, the seroprevalence of HBV infection in first-time blood donors was reduced significantly from 2001 to 2010 (p < 0.01).
Despite the decreasing of the global HBV infection, the use of serological markers for blood donor screenings is still important, since HBV remains a great risk for blood transfusion patients [3, 8]. In this study, the prevalence of HBV infection was 3.04% (95% CI: 2.7-3.4) and 0.19% (95% CI: 0.1-0.3) for total anti-HBc and HBsAg, respectively, suggesting the presence of HBV infection in first-time blood donors. However, this is a significant drop compared to 9.42% for total anti-HBc and 0.72% for HBsAg prevalence rate reported by Aguiar et al. .
Considering that HBV infection prevalence in blood donors depends on several factors, including the prevalence of the virus in the general population and the sensitivity of screening tests, it is reasonable to assume that the observed decline may have been due to the implementation of safety measures. Particularly because the screening tests used over the past decade were of similar sensitivity and performed in the same laboratory (Hemorrede Laboratory of Mato Grosso do Sul) with similar technical capabilities.
The cause of such declined rates is multifactorial and most likely due to the increase in vaccination programs conducted in the general population, implementation of a national strategy for blood safety and better data quality. Although over the past few years several studies have shown a decreasing trend of HBV seroprevalence among blood donors, others have found opposite results [10–16]. According to Niederhauser , immunization campaigns are efficient in reducing the risk of transfusion-transmitted HBV.
During the last four decades, blood donor profiles have changed as a result of the implementation of HBV screening, which has steadily reduced the risk of transmitting the virus through blood transfusion . Moreover, there is a cumulative effect of increasing public health awareness . In the population-based multicentric survey of hepatitis B infection in central-west Brazil, the prevalence of HBV rates classify the region as low endemic, rather than intermediate endemic as defined by previous studies . Such drop may be the explanation for the lower seroprevalence of HBV infection among blood donors than found by Aguiar et al. .
Significant increase in the seroprevalence of HBV was observed among older people. The lower prevalence among donors under 30 years old could be associated with hepatitis B vaccination program, which was initiated at the beginning of the 1990s in Brazil. Moreover, higher prevalence among older donors indicates a longer time of viral exposure, as corroborated by O’Brien et al. , Nkrumah et al.  and Seo et al. .
Statistical analysis showed no significant difference in HBV infection prevalence according to gender. This finding is similar to those found by Japhet et al. , Nascimento et al.  and Ataallah et al. .
Our results demonstrate the importance of updated information on HBV prevalence. The significant decrease of HBV infection between 2001 and 2010 among first-time blood donors suggests an improvement in the recruitment of safer donors, the positive impact of vaccination programs and the drop of HBV infection prevalence in the general population. This is a welcoming result since the safety of blood products also brings benefits to the general population and guides new prevention strategies.
Ethics committee approval
The present study was approved by the Ethics Committee of the Federal University of Mato Grosso do Sul (n. 1721/2010).
Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007, 45(2):507–9. 10.1002/hep.21513
European Association for the study of the liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009, 50(2):227–42. 10.1016/j.jhep.2008.10.001
Kwon SY, Lee CH: Epidemiology and prevention of hepatitis B virus infection. Korean J Hepatol 2011, 17(2):87–95. 10.3350/kjhep.2011.17.2.87
Silveira L, de Schiavon L L, Silva KP, Lopes TB, Zaccaron MR, Narciso-Schiavon JL: Clinical and epidemiological profile of blood donors with positive serology for viral hepatitis in southern Brazil. Rev Soc Bras Med Trop 2011, 44(3):269–73. 10.1590/S0037-86822011005000028
Pereira LM, Martelli CM, Merchán-Hamann E, Montarroyos UR, Braga MC, de Lima ML, Cardoso MR, Turchi MD, Costa MA, de Alencar LC, Moreira RC, Figueiredo GM, Ximenes RA, Hepatitis Study Group: Population-based multicentric survey of hepatitis B infection and risk factor differences among three regions in Brazil. Am J Trop Med Hyg 2009, 81(2):240–7.
Nascimento MC, Mayaud P, Sabino EC, Torres KL, Franceschi S: Prevalence of hepatitis B and C serological markers among first-time blood donors in Brazil: a multi-center serosurvey. J Med Virol 2008, 80(1):53–7. 10.1002/jmv.21046
Anjos GR, Martins RM, Carneiro MA, Brunini SM, Teles AS: Epidemiology of hepatitis B virus infection in first-time blood donors in the southwestern region of Goiás, central Brazil. Rev Bras Hematol Hemoter 2011, 33(1):38–42.
Candotti D, Allain JP: Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009, 51(4):798–809. 10.1016/j.jhep.2009.05.020
Aguiar JI, Aguiar E, Paniago A, Cunha R, Galvão L, Daher R: Prevalence of antibodies to hepatitis B core antigen in blood donors in the middle West region of Brazil. Mem Inst Oswaldo Cruz 2001, 96(2):185–7.
Khedmat H, Alavian SM, Miri SM, Amini M, Abolghasemi H, Hajibeigi B, Alaeddini F, Fallahian F: Trends in seroprevalence of hepatitis B, hepatitis C, HIV, and syphilis infections in iranian blood donors from 2003 to 2005. Hepat Mon 2009, 9(1):24–8.
Kafi-abad SA, Rezvan H, Abolghasemi H: Trends in prevalence of hepatitis B virus infection among Iranian blood donors, 1998–2007. Transfus Med 2009, 19(4):189–94. 10.1111/j.1365-3148.2009.00935.x
Chimparlee N, Oota S, Phikulsod S, Tangkijvanich P, Poovorawan Y: Hepatitis B and hepatitis C virus in Thai blood donors. Southeast Asian J Trop Med Public Health 2011, 42: 609–61.
Nkrumah B, Owusu M, Averu P: Hepatitis B and C viral infections among blood donors. a retrospective study from a rural community of Ghana. BMC Res Notes 2011, 4: 529. 10.1186/1756-0500-4-529
Dhruva GA, Agravat AH, Pujara KM: Seroprevalence of HIV, HBV, HCV and syphilis in blood donors in saurashtra region of Gujarat: declining trends over a period of 3½ years. OJHAS 2012, 11(1):1–2.
Durro V, Qyra S: Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999–2009. Virol J 2011, 8: 96. 10.1186/1743-422X-8-96
Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, Sack U: Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital. Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis 2010, 10: 111. 10.1186/1471-2334-10-111
Niederhauser C: Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med 2011, 2: 91–102.
Dwyre DM, Fernando LP, Holland PV: Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011, 100(1):92–8. 10.1111/j.1423-0410.2010.01426.x
Karki S, Ghimire P, Tiwari BR, Maharjan A, Rajkarnikar M: Trends in hepatitis B and hepatitis C seroprevalence among Nepalese blood donors. Jpn J Infect Dis 2008, 61(4):324–6.
O'Brien SF, Xi G, Fan W, Yi QL, Fearon MA, Scalia V, Goldman M: Epidemiology of hepatitis B in Canadian blood donors. Transfusion 2008, 48(11):2323–30. 10.1111/j.1537-2995.2008.01845.x
Seo DH, Whang DH, Song EY, Kim HS, Park Q: Prevalence of antibodies to hepatitis B core antigen and occult hepatitis B virus infections in Korean blood donors. Transfusion 2011, 51(8):1840–6. 10.1111/j.1537-2995.2010.03056.x
Japhet MO, Adesina OA, Donbraye E, Adewumi MO: Hepatitis B core IgM antibody (anti-HBcIgM) among hepatitis B surface antigen (HBsAg) negative blood donors in Nigeria. Virol J 2011, 8: 513. 10.1186/1743-422X-8-513
Ataallah TM, Hanan KA, Maysoun KS, Sadoon AA: Prevalence of hepatitis B and C among blood donors attending the National Blood Transfusion Center in Baghdad, Iraq from 2006–2009. Saudi Med J 2011, 32(10):1046.
We want to particularly acknowledge the Hematology Center of Mato Grosso do Sul (HEMOSUL).
The authors declare that there are no competing interests.
ASCL, ARCMC, SMFF and RVC designed the study. MAP and TSOT did most of the laboratory work. MST, SMFF and ASCL provided and checked the clinical data for patients. ASCL, ARCMC and SMFF wrote the manuscript. All authors reviewed the draft and approved the final version.
About this article
Cite this article
Lindenberg, A.d.S.C., Motta-Castro, A.R.C., Puga, M.A. et al. Decrease in hepatitis B prevalence among blood donors in Central-West Brazil. J Venom Anim Toxins Incl Trop Dis 19, 7 (2013). https://doi.org/10.1186/1678-9199-19-7
- Hepatitis B virus
- Blood donors